HAE · NYSE · Healthcare
Haemonetics Corporation (HAE) — Rank #180 by gross profitability (GP/assets 0.33) · ROE 11.6% · Piotroski F-Score 7 / 9.
As-of 2026-10-30 · CIK 0000313143 · all metrics point-in-time as of the filing date.
About
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions.
Show moreShow less
The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors.
The company was founded in 1971 and is headquartered in Boston, Massachusetts.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- MA
- Filer Category
- Large accelerated filer
- Fiscal Year End
- April 3
- Website
- haemonetics.com
Company Snapshot
P/E and reverse DCF are the primary valuation lenses at this stage.
Market Cap
—
P/E (annual)
—
P/S (annual)
—
P/B
—
P/OCF (annual)
—
Shareholder Yield
—
Employees
3,009
Industry
Medical Devices
Exchange
NYSE
10/12
Flags passed
HAE fails 2 critical flags
Passes 10 of 12 quality flags
- FAILRevenue declining YoY
Revenue contracted year over year
- FAILOperating margin declining
Operating margin lower than prior year
- PASSGross margin holding
- PASSDilution within 2%
- PASSFCF not negative from investment
- PASSDisclosure consistent
- PASSFree cash flow intact
- PASSPasses safety gate
- PASSBalance sheet stable
- PASSNo competitive retreat
- PASSSBC not compressing margin
- PASSNo valuation convergence
Strengths RPO outpacing revenue · Sequential beat (rev + EPS)
A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
1/2 passFCF yield, shareholder yield, and buyback activity are the primary reads at this stage.
Profitability
Does it make money well?
Warning: Operating margin declining, Revenue declining YoY · GP/assets 32nd percentile of 20 SIC 3841 peers
Gross profitability (GP / assets)
0.33
Primary signal (Novy-Marx).
32nd pctl of 20 SIC 3841 peers
Return on equity
11.6%
Gross margin
59.0%
26th pctl of 20 SIC 3841 peers
Revenue growth (YoY)
-2.0%
RPO growth (YoY)
8.5%
Remaining performance obligations growth — RPO > revenue = forward demand building.
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
4.5%
Revenue CAGR (5Y)
8.9%
Earnings CAGR (3Y)
-5.5%
FCF CAGR (3Y)
—
Cash Flow Health
Is the cash real?
No warning flags · FCF 168% above net income
Free cash flow
$260.44M
Operating cash flow minus capex.
Positive free cash flow
FCF vs net income
167.6%
(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.
FCF not below net income
Fails when free cash flow is below net income (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
2.5%
Stock-based comp intensity.
Balance Sheet Strength
Can it survive a storm?
No warning flags · net debt $950.77M, F-Score 7/9
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
1.83
19th of 19 SIC 3841 peers (best = lowest)
Current ratio
3.08×
53rd pctl of 20 SIC 3841 peers
Quick ratio
1.67×
Net cash
-$950.77M
Cash & equivalents minus total debt.
Piotroski F-Score
7 / 9
Fundamental-strength score (0-9).
Valuation
Is the price reasonable?
No warning flags
Capital allocation quality
Composite score
3.3 / 5
Lifecycle Phase History
Price History
Source filings on SEC EDGAR: 10-K annual reports · 10-Q quarterly reports